U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 176/60901 (6-11402-968)	SERIAL NO. 10/006,760
	APPLICANT Shohei Koide	
	FILING DATE November 19, 2001	GROUP ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO-PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS-LATION IF APPRO-PRIATE
	1	WO 98/56915	12/17/1998	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		2	Koide et al., "The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins," J. Mol. Biol. 284:1141-1151 (1998)
		3	Koide et al., "Stabilization of a Fibronectin Type III Domain by the Removal of Unfavorable Electrostatic Interactions on the Protein Surface," Biochemistry 40:10326-10333 (2001)
		4	Koide et al., "Probing Protein Conformational Changes Inside the Cell Using Designer Binding Proteins: Application to Nuclear Receptors," Protein Science 10(2):142 (2001)
		5	Richardson et al., "Phenotypic Knockout of the High-Affinity Human Interleukin 2 Receptor by Intracellular Single-Chain Antibodies Against the α Subunit of the Receptor," Proc. Natl. Acad. Sci. USA 92:3137-3141 (1995)
		6	Abedi, et al., "Green Fluorescent Protein as a Scaffold for Intracellular Presentation of Peptides," Nucleic Acids Research 26(2):623-630 (1998)
		7	Beste et al., "Small Antibody-like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," Proc. Natl. Acad. Sci. USA 96:1898-1903 (1999)
		8	Paige et al., "Estrogen Receptor (ER) Modulators Each Induce Distinct Conformational Changes in ER α and ER β," Proc. Natl. Acad. Sci. USA 96:3999-4004 (1999)
		9	Smith, "Patch Engineering: a General Approach for Creating Proteins That have New Binding Activities," TIBS 23:457-460 (1998)
		10	Taliana et al., "In Vivo Selection of Single-Chain Antibodies Using a Yeast Two-Hybrid System," Journal of Immunological Methods 238:161-172 (2000)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6 9; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 176/60901 (6-11402-968)	SERIAL NO. 10/006,760
	APPLICANT Shohei Koide	
	FILING DATE November 19, 2001	GROUP ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO-PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS-LATION IF APPRO-PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		11	Norris et al., "Peptide Antagonists of the Human Estrogen Receptor," Science 285:744-746 (1999)
		12	Chen et al., "Transcriptional Activation of the Human Estrogen Receptor by DDT Isomers and Metabolites in Yeast and MCF-7 Cells," Biochemical Pharmacology 53:1161-1172 (1997)
		13	Colas et al., "The Impact of Two-Hybrid and Related Methods on Biotechnology," TIBTech 16:355-363 (1998)
		14	Fields et al., "A Novel Genetic System to Detect Protein-Protein Interactions," Nature 340:245-246 ((1989)
		15	Mendelsohn et al., "Applications of Interaction Traps/Two-Hybrid Systems to Biotechnology Research," Biotechnology 5:482-486 (1994)
		16	Uetz et al., "Systematic and Large-Scale Two-Hybrid Screens," Current Opinion in Microbiology 3:303-308 (2000)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6 9; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.